On September 21, 2026 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that IP Australia has issued Patent Number 2020221280 related to Anixa’s breast cancer vaccine technology, exclusively licensed from Cleveland Clinic. This composition-of-matter patent protects the Company’s novel approach to breast cancer prevention and treatment in Australia through 2040, addressing a disease for which no preventive vaccine is currently approved anywhere in the world. The patent is titled, "Vaccine Adjuvants and Formulations," and the co-inventors are Dr. Justin Johnson and the late Dr. Vincent Tuohy, both of Cleveland Clinic.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
With this issued patent, Anixa continues to expand the international scope of its intellectual property portfolio, reinforcing its leadership in the field of cancer immunotherapy. The Australian patent complements Anixa’s existing patent portfolio in the United States and other key international markets, including Europe, China, and Japan, among others, further strengthening the Company’s global intellectual property estate. The expanded patent protection enhances Anixa’s ability to pursue future regulatory approvals, strategic partnerships and commercialization opportunities.
In a recently completed Phase 1 trial at Cleveland Clinic, funded by the U.S. Department of Defense, the vaccine met all major primary endpoints, was safe and well tolerated, and generated protocol defined immune responses in more than 74% of participants. These results support continued clinical development of the Company’s novel preventive and therapeutic breast cancer vaccine.
"This newly issued patent strengthens the global foundation we are building for our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue clinical development in the U.S., our growing international patent estate further strengthens our ability to pursue global opportunities and potentially partner with larger pharmaceutical companies for worldwide commercialization."
Breast cancer remains the most commonly diagnosed cancer among women worldwide, and while survival rates are high in Australia, the incidence rate has continued to increase. Despite significant advances in screening and treatment, there are currently no approved vaccines designed to prevent breast cancer.
Anixa’s vaccine is based on immunizing against human α-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer. This "retired" protein strategy, developed at Cleveland Clinic and licensed exclusively to Anixa, aims to selectively prime the immune system to prevent tumor formation while avoiding harm to normal tissue, particularly in aggressive forms of the disease such as triple-negative breast cancer.
By reinforcing its global patent estate, Anixa is laying the groundwork for future international development and commercialization strategies. The Company’s vaccine technology is designed to transform how the medical community approaches cancer prevention. If successful, the Company’s vaccine technology could represent one of the first preventive vaccine approaches targeting breast cancer, representing a potentially transformative advancement in cancer prevention.
(Press release, Anixa Biosciences, SEP 21, 2026, View Source [SID1234670977])